Advanced Biomed Inc(ADVB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.08 | Insider Own | 42.7% | Shs Outstand | 1.6M | Perf Week | -20.74% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.9M | Perf Month | -52.85% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 0.06% | Short Float | 1.03% | Perf Quarter | -70.44% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | -32.29% | Short Ratio | 0.08 | Perf Half Y | -43.77% |
| Sales | 0.00B | P/B | 12.78 | EPS next 5Y | - | ROA | -60.71% | Short Interest | 0.01M | Perf YTD | -48.94% |
| Book/sh | 0.23 | P/C | 492.09 | EPS past 3/5Y | -18.91% -25.94% | ROE | -78.78% | 52W High | -87.7% ($24.23) | Perf Year | -66.21% |
| Cash/sh | 0.01 | P/FCF | - | Sales past 3/5Y | - | ROIC | -61.6% | 52W Low | 9.96% ($2.71) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 14.35% | Gross Margin | -110.23% | Volatility(W/M) | 13.14% 12.91% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | -5535.26% | ATR (14) | 0.61 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.33 | EPS Q/Q | -1139.52% | Profit Margin | -5880.8% | RSI (14) | 24.09 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.33 | Sales Q/Q | - | SMA20 | -37.61% ($4.78) | Beta | 0.21 | Target Price | - |
| Payout | - | Debt/Eq | 0.08 | Earnings | - | SMA50 | -55.84% ($6.75) | Rel Volume | 0.14 | Prev Close | $3.04 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -50.03% ($5.96) | Avg Volume(3M) | 0.13M | Price | $2.98 |
| IPO | 2025/3/6 | Option/Short | No/Yes | Trades | 206 | Volume | 17,973 | Change | -1.97% |
🔬 is a microcap biotech company specializing in precision medicine diagnostics and research, headquartered in Tainan, Taiwan. Leveraging semiconductor microfluidic chip technology, the company detects and analyzes circulating tumor cells (CTCs) in the blood and develops precision medicine solutions, including its 3D cell culture platform A+PerfusC, which predicts responsiveness to anticancer treatment.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 14% of its average volume.
ADVB has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.1%.
Tap to view numbers
It ranks #42 of 44 in the industry
Based on market cap of $5M.
XWEL#40 XWELL Inc $7M PER - 
NDRA#41 ENDRA Life Sciences Inc $7M PER - ADVB#42 Advanced Biomed Inc $5M PER - 
BIAF#43 BioAffinity Technologies Inc $4M PER - 
ISPC#44 iSpecimen Inc $2M PER - 
FAQ
What kind of company is ADVB?
ADVB belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ADVB?
The market cap of ADVB is approximately $5M, ranking 5,638 within its sector.
What is the 52-week high and low for ADVB?
ADVB has recorded a 52-week high of $24.23 and a low of $2.71.
